Pediatric myelodysplastic syndromes.
A new classification of myelodysplastic and myeloproliferative diseases in childhood has greatly facilitated the diagnosis of these uncommon disorders. Because hematopoietic stem cell transplantation (HSCT) can cure more than half of the affected children, palliative treatment strategies often applied in adult myelodysplastic syndrome (MDS) are of little importance in pediatric MDS. Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly.
Niemeyer
Charlotte Marie
CM
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany. niemeyer@kikli.ukl.uni-freiburg.de
Kratz
Christian Peter
CP
Hasle
Henrik
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*